Tags: Inflammation
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
October 15, 2019
$3.2 Million in New Funding Focused on Biomarkers and Moving Toward New Therapies
These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.
announcements
May 10, 2019
$7.1 Million in New Funding Illustrates the ADDF’s Strong Support of a Diverse Pipeline
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
announcements
September 13, 2018
$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments
The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.
announcements
July 13, 2018
New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction
The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.
announcements
May 1, 2018
Partnership with FNIH Will Drive New Biomarkers for Alzheimer’s
The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease.
announcements
January 8, 2018
$1.8 Million in New Funding Supports Clinical Stage Treatments
The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.
announcements
November 14, 2017
Three New Grants Keep Promising Programs Forging Ahead
The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.
blog
October 24, 2017
Combination Therapy: The Right Approach for Alzheimer’s
Learn why combination therapy holds such promise for treating Alzheimer's disease, and why Amylyx's drug is the first such therapy we are funding.
announcements
October 24, 2017
Innovative Alzheimer’s Combination Therapy Trial Supported by New Joint Funding Initiative
We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.
announcements
September 13, 2017
18th Annual Conference on Alzheimer’s Drug Discovery Showcases Non-Amyloid Research
Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.
blog
September 5, 2017
Driving Innovation in Alzheimer’s Therapies
At our 18th Annual Conference on Alzheimer’s Drug Discovery in Jersey City, the impact of our approach will take center stage.
blog
August 17, 2017
Inflammation, The Driver of Alzheimer’s Disease?
A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.
announcements
March 7, 2017
$4 Million in New Grants Support Several First-in-Class Dementia Treatments
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
blog
January 10, 2017
Top Five Alzheimer’s Advances in 2016
In 2016, we made great progress toward finding drugs to prevent and treat Alzheimer’s, as our top five advances demonstrate.
announcements
January 9, 2017
$2.5 Million in New Grants Advance Clinical Trials of Alzheimer’s Treatments
We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.
announcements
September 29, 2016
New Clinical Trial Will Test Cancer Drug as Alzheimer’s Treatment
Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."
announcements
September 22, 2016
Vivreon Biosciences Awarded Grant to Advance Drug Program Targeting Neuroinflammation
Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF) to develop compounds that targets brain inflammation in Alzheimer's disease.
announcements
September 21, 2016
$1.7 Million Grant Supports Promising Drug That Targets Cannabinoid Receptor
With a $1.7 million award from the ADDF, a new biotech created by Cleveland Clinic Innovations is developing a novel drug that reduces inflammation in the brain by targeting a cannabinoid receptor.
announcements
September 13, 2016
Dr. D. Martin Watterson Wins Second Melvin R. Goodes Prize
Dr. Watterson has identified a number of new classes of Central Nervous System drugs.
announcements
September 12, 2016
Three New Grants Support Promising Treatments for Alzheimer’s Disease
The ADDF awarded three new grants in July and August for potential new treatments for Alzheimer's and other dementias.
announcements
May 10, 2016
Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development
The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.
announcements
February 25, 2016
Five New Grants Support Drug Discovery and Prevention
Grants awarded in the first two months of 2016 support researchers in the U.S. and Middle East pursuing drug programs, prevention studies, and research to accelerate clinical trials.
announcements
January 5, 2016
Five New Research Grants Support Clinical and Early-Stage Programs
Funded Researchers are pursuing diverse targets to treat Alzheimer's disease.
announcements
August 26, 2015
ADDF and Harrington Discovery Institute Announce 2015 Award Recipients
Collaboration advances development of therapeutics for the treatment of Alzheimer’s Disease.
announcements
March 17, 2015
GliaCure Receives $1 Million Grant for Alzheimer’s Clinical Trial
The ADDF awarded $1 million to GliaCure to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer's disease.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024